Skip to main content
Premium Trial:

Request an Annual Quote

Eragen Signs up Aventis for Software License Renewal, Services

NEW YORK, July 15 -  EraGen Biosciences has signed up  Aventis for contract services and a renewal of a licensing agreement for the company's genomic-based software analysis system, EraGen said today.


Under the agreement,  Aventis will be able to access EraGen's technical support group for drug discovery using EraGen's Master Catalog software.


Master Catalog uses the evolutionary characteristics of 130 genomes, as well as Pathogenome, a proprietary database, for in silico prediction of proteins that are potential drug targets.


Eragen is based in Madison, Wis.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.